Novartis Breakthrough: Promising Results for Sjögren's Syndrome Treatment

Swiss pharmaceutical giant Novartis reports successful Phase III trials for Ianalumab therapy, potentially offering the first targeted treatment for Sjögren's Syndrome patients worldwide.